Innovotech's Biofilm Test Shows Significant Differences in Antibiotic Choices for Cystic Fibrosis Patients Compared to Conventio
October 18 2010 - 8:00AM
Marketwired
Innovotech Inc. (TSX VENTURE: IOT), a pioneer in the field of
biofilm product development, today announced that an ongoing
clinical trial using the Company's bioFILM PA™ test shows that in
71% of cases, the test suggests different antibiotic treatment
choices (p less than 0.0001) for Cystic Fibrosis (CF) patients with
Pseudomonas aeruginosa (PA) chronic lung infections compared to
conventional testing.
Drs. Valerie Waters and Yvonne Yau of The Hospital for Sick
Children in Toronto will be presenting the results in a poster at
The 24th Annual North American Cystic Fibrosis Conference in
Baltimore, October 21st to October 23rd. The poster provides an
update on the randomized double blind controlled clinical trial
currently underway, the purpose of which is to determine if the use
of the bioFILM PA™ test leads to improved CF patient outcomes.
"To date, physicians have based much of their treatment for
Cystic Fibrosis lung infections on a combination of conventional
susceptibility testing and educated guesses," said Ken Boutilier,
President and CEO of Innovotech Inc. "It is our understanding from
speaking with physicians that there are many occasions when
conventional testing indicates that the bacteria is resistant to
all available antibiotics. The bioFILM PA™ test has provided
results which question the validity of current methods and may
ultimately lead to differences in patient outcomes."
Innovotech's team will be in attendance at the conference.
Please visit booth 718 for more information regarding bioFILM PA™
or contact Innovotech directly.
bioFILM PA™ is the world's first biofilm susceptibility test,
designed to assist physicians in the selection of the most
effective combination antibiotic treatment of patients with PA
infections, such as those that occur in patients with CF. Biofilms
are known to be present in CF lung infections, and are up to 1000
times more difficult to treat than non-biofilm infections.
According to the National Institute of Health, 80% of all human
infections are biofilm-related. PA infections are also common in
patients with hospital-acquired infections such as
ventilator-associated pneumonia and those found in patients with
burns and wounds.
Cystic Fibrosis is a genetic disease affecting predominantly
children and young adults and is one of the most recognized biofilm
diseases. CF patients are prone to frequent lung infections that
are often fatal.
About The 24th Annual North American Cystic Fibrosis
Conference
The North American Cystic Fibrosis Conference is the largest
gathering of cystic fibrosis (CF) professionals in the world,
providing superior continuing medical education and a
multi-disciplinary approach to the advancement of CF research,
treatments and care. For more information visit
https://www.nacfconference.org/Default2010.asp.
About Innovotech Inc.:
Innovotech Inc. is a pioneer in the field of biofilm product
development, focused on providing innovative and practical
solutions to medical, agricultural and industrial problems caused
by microbial biofilms. Biofilms are responsible for a host of
diseases both in human health and agriculture due to their inherent
resistance to existing antibiotics and disinfectants. There are
currently no antibiotics, disinfectants, diagnostics or regulatory
standards designed specifically for biofilm-forming organisms.
Innovotech currently has two products in advanced stages of
development: bioFILM PA™, the first diagnostic test to assist
physicians in the selection of the most effective combination
antibiotic treatment of patients with biofilm-based chronic lung
infections and Agress™ a unique, environmentally friendly seed
treatment and plant spray designed to protect crops against both
bacterial and fungal infections.
This document may contain forward-looking statements that are
predictive in nature and subject to risks and uncertainties that
cannot be predicted or quantified; consequently, actual results may
differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or
contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of
predicting regulatory outcomes; changes in the value of the
Canadian dollar; the Company's reliance on a small number of
customers including government organizations; fluctuations in
operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and
potential costs associated with its defense; the Company's exposure
to lawsuits and other matters beyond the control of management.
Should known or unknown risks or uncertainties materialize, or
should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company
undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable
law.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Innovotech Inc. Ken Boutilier President and CEO (780)
448-0585 ext. 221 (780) 424-0941 (FAX) ken.boutilier@innovotech.ca
www.innovotech.ca
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024